NYSE:WAT - Waters Stock Price, Forecast & News

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its board has approved a stock buyback program on Tuesday, April 24th 2018, which authorizes the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 18.2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its stock is undervalued.

Waters Co. (NYSE:WAT) issued its quarterly earnings data on Tuesday, October, 29th. The medical instruments supplier reported $2.13 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $2.13. The medical instruments supplier earned $577.28 million during the quarter, compared to analysts' expectations of $588.35 million. Waters had a net margin of 23.98% and a return on equity of 77.73%. The company's revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.92 EPS. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Wednesday, January 22nd 2020. View Earnings Estimates for Waters.

Waters updated its fourth quarter earnings guidance on Tuesday, October, 29th. The company provided EPS guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus estimate of $3.23. The company issued revenue guidance of $715-729 million, compared to the consensus revenue estimate of $735.22 million.

9 brokers have issued 12-month target prices for Waters' stock. Their forecasts range from $177.00 to $260.00. On average, they expect Waters' stock price to reach $213.50 in the next twelve months. This suggests that the stock has a possible downside of 8.8%. View Analyst Price Targets for Waters.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 4 sell ratings and 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

News headlines about WAT stock have trended somewhat negative this week, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Waters earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Waters.

Some companies that are related to Waters include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), Home Depot (HD), Alibaba Group (BABA), Honeywell International (HON), CVS Health (CVS), Raytheon (RTN), Verizon Communications (VZ), Cisco Systems (CSCO), QUALCOMM (QCOM) and Johnson & Johnson (JNJ).

Waters' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (8.65%), State Street Corp (4.67%), Marathon Asset Management LLP (0.69%), Man Group plc (0.69%), Select Equity Group L.P. (0.67%) and Beck Mack & Oliver LLC (0.58%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Edward Conard, Elizabeth B Rae, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Robert G Carson, Terrence P Kelly and Thomas P Salice. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department, State Street Corp, First Trust Advisors LP, Robecosam AG, Fenimore Asset Management Inc., Pictet Asset Management Ltd., Marathon Asset Management LLP and Harvey Investment Co. LLC. Company insiders that have sold Waters company stock in the last year include Edward Conard, Elizabeth B Rae, Ian King, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Robert G Carson, Terrence P Kelly and Thomas P Salice. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Select Equity Group L.P., Anchor Capital Advisors LLC, State of New Jersey Common Pension Fund D, Man Group plc, Assenagon Asset Management S.A., California Public Employees Retirement System and Ferguson Wellman Capital Management Inc.. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $234.11.

Waters has a market capitalization of $15.08 billion and generates $2.42 billion in revenue each year. The medical instruments supplier earns $593.79 million in net income (profit) each year or $8.29 on an earnings per share basis. Waters employs 7,200 workers across the globe.View Additional Information About Waters.

The official website for Waters is http://www.waters.com/.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]